Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 13 | 2024 | 117 | 6.170 |
Why?
|
| Prostatic Neoplasms | 23 | 2023 | 1769 | 4.080 |
Why?
|
| Medicare | 19 | 2023 | 425 | 3.550 |
Why?
|
| Urologists | 7 | 2024 | 29 | 3.260 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2024 | 401 | 2.980 |
Why?
|
| Drug Industry | 4 | 2023 | 54 | 2.480 |
Why?
|
| Accountable Care Organizations | 5 | 2022 | 14 | 2.390 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2024 | 601 | 2.120 |
Why?
|
| Cystectomy | 6 | 2024 | 110 | 1.970 |
Why?
|
| Prostatectomy | 9 | 2023 | 477 | 1.930 |
Why?
|
| Prostate-Specific Antigen | 9 | 2022 | 360 | 1.910 |
Why?
|
| Prostatic Hyperplasia | 3 | 2023 | 91 | 1.700 |
Why?
|
| United States | 32 | 2024 | 6987 | 1.500 |
Why?
|
| Prostate | 5 | 2022 | 393 | 1.470 |
Why?
|
| Urologic Diseases | 2 | 2023 | 44 | 1.450 |
Why?
|
| Physicians | 4 | 2024 | 690 | 1.260 |
Why?
|
| Cost Savings | 5 | 2022 | 69 | 1.250 |
Why?
|
| Hematuria | 2 | 2024 | 50 | 1.130 |
Why?
|
| Kidney Neoplasms | 7 | 2021 | 638 | 1.110 |
Why?
|
| Erectile Dysfunction | 3 | 2023 | 75 | 1.080 |
Why?
|
| Male | 53 | 2024 | 42410 | 1.080 |
Why?
|
| Humans | 73 | 2024 | 89349 | 1.060 |
Why?
|
| Aged | 36 | 2024 | 19165 | 1.050 |
Why?
|
| Lymph Node Excision | 5 | 2019 | 220 | 0.980 |
Why?
|
| Cystoscopy | 1 | 2024 | 39 | 0.930 |
Why?
|
| Aortic Valve Stenosis | 3 | 2021 | 143 | 0.930 |
Why?
|
| Circumcision, Male | 1 | 2023 | 19 | 0.900 |
Why?
|
| Pyrimidinones | 1 | 2023 | 38 | 0.900 |
Why?
|
| Penile Induration | 1 | 2023 | 7 | 0.880 |
Why?
|
| Surgeons | 2 | 2024 | 248 | 0.850 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 52 | 0.850 |
Why?
|
| Health Care Sector | 1 | 2021 | 13 | 0.790 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2020 | 437 | 0.790 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 17 | 0.790 |
Why?
|
| Equipment and Supplies | 1 | 2021 | 28 | 0.780 |
Why?
|
| Conflict of Interest | 1 | 2021 | 68 | 0.760 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 377 | 0.750 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2019 | 178 | 0.740 |
Why?
|
| Health Expenditures | 2 | 2020 | 91 | 0.730 |
Why?
|
| Biomedical Technology | 1 | 2020 | 21 | 0.730 |
Why?
|
| Publishing | 1 | 2021 | 90 | 0.730 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 206 | 0.710 |
Why?
|
| Drug Prescriptions | 2 | 2019 | 144 | 0.710 |
Why?
|
| Health Policy | 2 | 2020 | 185 | 0.710 |
Why?
|
| Episode of Care | 1 | 2019 | 7 | 0.700 |
Why?
|
| Robotic Surgical Procedures | 6 | 2022 | 306 | 0.700 |
Why?
|
| Conservative Treatment | 1 | 2019 | 21 | 0.680 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 60 | 0.670 |
Why?
|
| Meniscectomy | 1 | 2018 | 3 | 0.650 |
Why?
|
| Vertebroplasty | 1 | 2018 | 8 | 0.650 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 41 | 0.640 |
Why?
|
| Office Visits | 1 | 2019 | 50 | 0.630 |
Why?
|
| Urological Agents | 1 | 2018 | 5 | 0.620 |
Why?
|
| Ureteral Calculi | 1 | 2017 | 10 | 0.600 |
Why?
|
| Health Care Costs | 1 | 2019 | 235 | 0.600 |
Why?
|
| Aftercare | 1 | 2018 | 87 | 0.580 |
Why?
|
| Retrospective Studies | 17 | 2024 | 9057 | 0.560 |
Why?
|
| Hospitals, Pediatric | 1 | 2017 | 117 | 0.550 |
Why?
|
| Aged, 80 and over | 11 | 2021 | 6811 | 0.540 |
Why?
|
| Patient Participation | 1 | 2018 | 224 | 0.530 |
Why?
|
| Pneumoperitoneum | 1 | 2015 | 4 | 0.520 |
Why?
|
| Databases, Factual | 4 | 2023 | 855 | 0.520 |
Why?
|
| Telemedicine | 1 | 2018 | 188 | 0.510 |
Why?
|
| Quality of Health Care | 1 | 2018 | 385 | 0.500 |
Why?
|
| Treatment Outcome | 14 | 2022 | 8241 | 0.500 |
Why?
|
| Kidney Calculi | 1 | 2017 | 343 | 0.460 |
Why?
|
| Middle Aged | 22 | 2024 | 25974 | 0.400 |
Why?
|
| Hospitalization | 1 | 2017 | 877 | 0.390 |
Why?
|
| Group Practice | 2 | 2021 | 7 | 0.380 |
Why?
|
| Female | 23 | 2024 | 46200 | 0.370 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 981 | 0.360 |
Why?
|
| Lymph Nodes | 3 | 2020 | 548 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3448 | 0.340 |
Why?
|
| Time Factors | 7 | 2024 | 5337 | 0.330 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2284 | 0.320 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 435 | 0.320 |
Why?
|
| Registries | 3 | 2023 | 784 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2024 | 487 | 0.290 |
Why?
|
| Neoplasms | 1 | 2022 | 3041 | 0.280 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2019 | 121 | 0.270 |
Why?
|
| Pelvis | 2 | 2017 | 96 | 0.260 |
Why?
|
| Adult | 11 | 2024 | 26607 | 0.240 |
Why?
|
| Phenylthiohydantoin | 3 | 2020 | 48 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 1365 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 576 | 0.230 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 502 | 0.230 |
Why?
|
| Physician Assistants | 1 | 2024 | 21 | 0.230 |
Why?
|
| Industry | 1 | 2023 | 17 | 0.220 |
Why?
|
| Men's Health | 1 | 2023 | 6 | 0.220 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 83 | 0.220 |
Why?
|
| Pyrrolidines | 1 | 2023 | 59 | 0.220 |
Why?
|
| Metabolic Syndrome | 1 | 2024 | 123 | 0.220 |
Why?
|
| Cryotherapy | 1 | 2022 | 30 | 0.210 |
Why?
|
| Insurance Carriers | 1 | 2022 | 6 | 0.210 |
Why?
|
| Androstenes | 2 | 2020 | 45 | 0.210 |
Why?
|
| Linear Models | 1 | 2023 | 421 | 0.210 |
Why?
|
| Burnout, Professional | 1 | 2024 | 102 | 0.200 |
Why?
|
| Patient Care | 1 | 2023 | 102 | 0.200 |
Why?
|
| Medicare Part D | 2 | 2020 | 10 | 0.200 |
Why?
|
| Seminal Vesicles | 1 | 2022 | 39 | 0.200 |
Why?
|
| Financial Statements | 1 | 2021 | 3 | 0.200 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.200 |
Why?
|
| Professional Misconduct | 1 | 2021 | 25 | 0.200 |
Why?
|
| Adipose Tissue | 2 | 2015 | 259 | 0.200 |
Why?
|
| Neoplasm Grading | 1 | 2023 | 374 | 0.190 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1719 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 91 | 0.190 |
Why?
|
| Image-Guided Biopsy | 1 | 2021 | 68 | 0.190 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2021 | 67 | 0.190 |
Why?
|
| Disclosure | 1 | 2021 | 110 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 1 | 2022 | 184 | 0.180 |
Why?
|
| Inpatients | 1 | 2023 | 310 | 0.180 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 2018 | 0.180 |
Why?
|
| Reimbursement, Incentive | 1 | 2020 | 37 | 0.180 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 253 | 0.170 |
Why?
|
| Seminoma | 1 | 2019 | 13 | 0.170 |
Why?
|
| Retroperitoneal Space | 1 | 2019 | 38 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2022 | 2869 | 0.170 |
Why?
|
| Dementia | 1 | 2021 | 194 | 0.170 |
Why?
|
| Child | 2 | 2023 | 7173 | 0.170 |
Why?
|
| Ureteroscopes | 1 | 2019 | 3 | 0.170 |
Why?
|
| Cost Control | 1 | 2019 | 45 | 0.160 |
Why?
|
| Disposable Equipment | 1 | 2019 | 21 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 140 | 0.160 |
Why?
|
| Prognosis | 5 | 2017 | 3783 | 0.160 |
Why?
|
| Hematologic Tests | 1 | 2018 | 15 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2019 | 280 | 0.160 |
Why?
|
| Solifenacin Succinate | 1 | 2018 | 6 | 0.160 |
Why?
|
| Michigan | 1 | 2018 | 53 | 0.160 |
Why?
|
| Acetanilides | 1 | 2018 | 6 | 0.160 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2018 | 31 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 113 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 2415 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2018 | 26 | 0.150 |
Why?
|
| Biopsy | 1 | 2022 | 1184 | 0.150 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 416 | 0.150 |
Why?
|
| Databases as Topic | 1 | 2018 | 94 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 44 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2017 | 123 | 0.150 |
Why?
|
| Adrenal Gland Diseases | 1 | 2017 | 14 | 0.150 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 207 | 0.150 |
Why?
|
| Watchful Waiting | 1 | 2018 | 63 | 0.150 |
Why?
|
| Cardiac Catheterization | 1 | 2019 | 303 | 0.150 |
Why?
|
| Adrenalectomy | 1 | 2017 | 45 | 0.150 |
Why?
|
| Thiazoles | 1 | 2018 | 128 | 0.150 |
Why?
|
| Urinary Calculi | 1 | 2017 | 46 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2480 | 0.150 |
Why?
|
| Health Status | 1 | 2019 | 371 | 0.150 |
Why?
|
| Incidence | 3 | 2017 | 1595 | 0.140 |
Why?
|
| Risk | 1 | 2019 | 657 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 329 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1714 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 461 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 499 | 0.140 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 23 | 0.140 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2016 | 10 | 0.140 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2017 | 81 | 0.140 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2018 | 90 | 0.140 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2016 | 8 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2020 | 352 | 0.130 |
Why?
|
| Androgens | 1 | 2017 | 176 | 0.130 |
Why?
|
| Indoles | 1 | 2018 | 314 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 588 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2017 | 2303 | 0.130 |
Why?
|
| Hyaluronic Acid | 1 | 2016 | 49 | 0.130 |
Why?
|
| Urologic Surgical Procedures | 1 | 2017 | 147 | 0.130 |
Why?
|
| Mass Screening | 1 | 2020 | 636 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 860 | 0.130 |
Why?
|
| Insufflation | 1 | 2015 | 10 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2015 | 29 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2018 | 341 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 88 | 0.120 |
Why?
|
| Quality of Life | 2 | 2021 | 1668 | 0.120 |
Why?
|
| Operative Time | 1 | 2015 | 143 | 0.120 |
Why?
|
| Pressure | 1 | 2015 | 165 | 0.120 |
Why?
|
| Interleukin-2 | 1 | 2015 | 251 | 0.120 |
Why?
|
| Hemoglobins | 1 | 2015 | 192 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2024 | 1045 | 0.120 |
Why?
|
| Dissent and Disputes | 1 | 2014 | 29 | 0.120 |
Why?
|
| Nitriles | 3 | 2020 | 160 | 0.120 |
Why?
|
| Medical Futility | 1 | 2014 | 31 | 0.120 |
Why?
|
| Sex Factors | 1 | 2017 | 1066 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 275 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 308 | 0.110 |
Why?
|
| Benzamides | 3 | 2020 | 237 | 0.110 |
Why?
|
| Logistic Models | 1 | 2017 | 1213 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2015 | 0.110 |
Why?
|
| Adolescent | 4 | 2022 | 9263 | 0.110 |
Why?
|
| Patient Safety | 1 | 2015 | 218 | 0.110 |
Why?
|
| Age Factors | 1 | 2017 | 1870 | 0.110 |
Why?
|
| Palliative Care | 1 | 2014 | 264 | 0.100 |
Why?
|
| Kidney | 1 | 2016 | 1147 | 0.090 |
Why?
|
| Digital Rectal Examination | 1 | 2010 | 7 | 0.090 |
Why?
|
| Ureteral Diseases | 1 | 2010 | 14 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 3731 | 0.090 |
Why?
|
| Algorithms | 1 | 2018 | 1877 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1265 | 0.080 |
Why?
|
| Catheterization | 1 | 2010 | 237 | 0.080 |
Why?
|
| Coronary Artery Bypass | 2 | 2021 | 234 | 0.080 |
Why?
|
| Survival Rate | 3 | 2020 | 1901 | 0.080 |
Why?
|
| Prosthesis-Related Infections | 1 | 2008 | 61 | 0.080 |
Why?
|
| Orchiectomy | 2 | 2019 | 72 | 0.080 |
Why?
|
| Kallikreins | 2 | 2020 | 49 | 0.080 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2008 | 89 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 120 | 0.070 |
Why?
|
| Penile Erection | 2 | 2016 | 22 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2008 | 243 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3666 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 282 | 0.060 |
Why?
|
| Administration, Intravesical | 1 | 2024 | 34 | 0.060 |
Why?
|
| Censuses | 1 | 2024 | 7 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2017 | 794 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2010 | 850 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 98 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2024 | 231 | 0.060 |
Why?
|
| Young Adult | 4 | 2019 | 6312 | 0.050 |
Why?
|
| Forecasting | 1 | 2024 | 306 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 122 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1214 | 0.050 |
Why?
|
| Gallium Isotopes | 1 | 2022 | 2 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 148 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2022 | 31 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 2401 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 618 | 0.050 |
Why?
|
| Perineum | 1 | 2021 | 36 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 30 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2021 | 123 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4289 | 0.040 |
Why?
|
| Income | 1 | 2020 | 84 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 590 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 299 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 197 | 0.040 |
Why?
|
| Drug Costs | 1 | 2020 | 63 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 192 | 0.040 |
Why?
|
| Colectomy | 1 | 2021 | 172 | 0.040 |
Why?
|
| Laparoscopy | 2 | 2017 | 773 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 306 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2020 | 120 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2020 | 360 | 0.040 |
Why?
|
| Testis | 1 | 2019 | 152 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 682 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2015 | 1534 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 147 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2019 | 234 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 851 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 295 | 0.040 |
Why?
|
| Abiraterone Acetate | 1 | 2017 | 12 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 2017 | 28 | 0.040 |
Why?
|
| Trauma, Nervous System | 1 | 2016 | 5 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 306 | 0.030 |
Why?
|
| Specialties, Surgical | 1 | 2017 | 66 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2016 | 60 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 736 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 2016 | 126 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 232 | 0.030 |
Why?
|
| Penis | 1 | 2016 | 60 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2016 | 159 | 0.030 |
Why?
|
| Taiwan | 1 | 2015 | 23 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2015 | 31 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 98 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 470 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 193 | 0.030 |
Why?
|
| Testosterone | 1 | 2017 | 276 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 302 | 0.030 |
Why?
|
| Internationality | 1 | 2015 | 69 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2016 | 354 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 1057 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 815 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 887 | 0.030 |
Why?
|
| Ethics Committees | 1 | 2014 | 9 | 0.030 |
Why?
|
| Negotiating | 1 | 2014 | 20 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2014 | 52 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 83 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 1237 | 0.030 |
Why?
|
| Patient Preference | 1 | 2014 | 111 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 988 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2758 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 296 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 5498 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2013 | 236 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1941 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2017 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 1109 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1652 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 60 | 0.020 |
Why?
|
| Communication | 1 | 2014 | 459 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1717 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 4041 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2010 | 217 | 0.020 |
Why?
|
| Ureter | 1 | 2010 | 93 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 2558 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 625 | 0.020 |
Why?
|
| Illinois | 1 | 2008 | 480 | 0.020 |
Why?
|
| Animals | 2 | 2017 | 27369 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 1135 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1549 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 949 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 11761 | 0.010 |
Why?
|